E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy

類似資料

• Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations
  著者:: Claudiani, Simone, 等
  出版事項: (2020)
• MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia
  著者:: Claudiani, Simone, 等
  出版事項: (2019)
• Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
  著者:: Marin, David, 等
  出版事項: (2012)
• Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors
  著者:: Nteliopoulos, Georgios, 等
  出版事項: (2019)
• Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy
  著者:: Neelakantan, Pratap, 等
  出版事項: (2012)